Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

embership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be use
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Huge event with 36,000+ global professionals is ... analysis and forecasting   CPhI Worldwide , ... most successful show to date with pre-audit figures estimating ... year in Paris , the show ... countries representing every step of the pharmaceutical supply chain ...
(Date:10/31/2014)... Ill. (PRWEB) October 31, 2014 Jeffrey ... Department of Historical Studies within the College of Arts ... SIUE to record the history of alcohol-based fuels in ... and many others have been working to build Illinois’ ... important but overlooked aspect of the state's agricultural and ...
(Date:10/31/2014)... 31, 2014 ENVIRON , ... announced today that Dr. Harvey Clewell III has ... will work closely with senior professionals in ENVIRON’s ... to serve at The Hamner Institutes for Health ... Carolina, where he is Director, Center for Human ...
(Date:10/30/2014)... LONDON , October 30, 2014 ... Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... PCYC ), Synthetic Biologics Inc. (NYSE MKT: SYN), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,549.23, down 0.33%, the Dow Jones ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... ... Capital,s client Neuren Pharmaceuticals Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible note private ... as Neuren,s exclusive placement agent and advisor. , ... New York (PRWEB) November 23, 2009 -- The independent ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced that it has ... common stock will be,suspended as of November 30, 2009 and a ... will remove deCODE,s common stock,from listing on Nasdaq, unless the company ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced the approval of all of ... Delaware,(the "Bankruptcy Court"). deCODE last week filed a voluntary petition for,relief under ... The orders issued by the Bankruptcy Court allow ...
Cached Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
(Date:10/29/2014)... and gas production are well over recommended levels in ... journal Environmental Health . High levels of benzene, ... the first to be based on community sampling by ... used to supplement official air-quality monitoring programs. , Unconventional ... readily flow to the surface. This is because they ...
(Date:10/29/2014)... been blamed for increasing the risk of a ... history of schizophrenia, are widely accepted. Others, such ... parasite transmitted by soil, undercooked meat and cat ... new study by Gary Smith, professor of population ... School of Veterinary Medicine, used epidemiological modeling methods ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... developed a small-molecule inhibitor of a protein that plays ... they show that the inhibitor can halt the growth ... culture. The findings are reported in companion papers reported ... Jan-Michael Peters of the Research Institute of Molecular Pathology ...
... developed at the University of Toronto is revealing biochemical ... could one day pave the way for pharmaceutical applications. ... issue of Molecular Cell describes how U of T ... test for proteins that play an important role in ...
... popular game fish mistaken by scientists for a dog ... reefs of the Abrolhos region of the South Atlantic ... discovery of Lutjanus alexandrei, a new snapper species that ... of Conservation International (CI) and Kenyon Lindeman of Environmental ...
Cached Biology News:New protein inhibitor impedes growth of cancerous cells 2Technology reveals 'lock and key' proteins behind diseases 2New species of snapper discovered in Brazil 2
... mg/L sodium pyruvate, 50 mg/L streptomycin sulfate, ... calcium chloride, and magnesium chloride. The use ... tissue culture is generally attributed to early ... Ringer developed a solution of inorganic salts ...
... dramatic breakthrough in accurate, small-volume bulk dispensing. Dispensing ... micro 1 has unique advantages not found in ... never needs re-calibration as do other 1mL dispensers. ... LCD Display , Graphical Row Selection , 96-,384- ...
... Rabbit polyclonal to Rad51 ( Abpromise ... Antigen: Synthetic peptide: ... N terminal amino acids 15-29 of ... Gene ID: 5888 ...
... performance agitation and temperature control for microbiology ... wells independently and is suitable for DASGIP ... working volume. Its temperature ranges from approximately ... well is equipped with an individual electrical ...
Biology Products: